Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Operating Expenses for 10 consecutive years, with $104.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 25.55% to $104.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $381.8 million, a 3.5% decrease, with the full-year FY2025 number at $381.8 million, down 3.5% from a year prior.
  • Operating Expenses was $104.3 million for Q4 2025 at Rhythm Pharmaceuticals, roughly flat from $104.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $165.9 million in Q1 2024 to a low of $34.4 million in Q1 2021.
  • A 5-year average of $70.8 million and a median of $65.7 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 159.15% in 2024, then tumbled 51.94% in 2025.
  • Rhythm Pharmaceuticals' Operating Expenses stood at $52.8 million in 2021, then decreased by 3.62% to $50.9 million in 2022, then grew by 28.7% to $65.5 million in 2023, then grew by 26.85% to $83.1 million in 2024, then grew by 25.55% to $104.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Operating Expenses are $104.3 million (Q4 2025), $104.0 million (Q3 2025), and $93.8 million (Q2 2025).